Elion Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• Antifungal Comparator · Infectious Disease
  Antifungal mechanism involves inhibiting fungal cell wall synthesis
• EL219 · Oncology
  EL219 is an immunostimulatory agent designed to activate innate immune responses against cancer.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Elion Therapeutics, Inc. portfolio CI brief
• Elion Therapeutics, Inc. pipeline updates RSS